Organoids Market Size Report | Analysis and Forecast 2028

report image

Organoids Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Stomach, Intestine, Liver, Pancreas, Lung, Brain, Kidney, and Others), Application (Developmental Biology, Disease Pathology of Infectious Disease, Regenerative Medicine, Drug Toxicity & Efficacy Testing, Drug Discovery & Personalized Medicine, and Others), Source (Pluripotent Stem Cells and Organ-specific Adult Stem Cells), and Geography

Publication Month: May 2023 | Report Code: TIPRE00017616 | No. of Pages: 196 | Category: Biotechnology | Status: Published

[Research Report] The organoids market size is expected to grow from US$ 2,507.28 million in 2022 to US$ 8,121.45 million by 2028; it is estimated to record a CAGR of 21.8% from 2023 to 2028.

The organoids market is segmented based on type, application, source, and geography. The report offers insights and in-depth analysis of the market, emphasizing various parameters such as dynamics, trends, and opportunities of the market and competitive landscape analysis of leading market players across the region.

Strategic Insights

Report Coverage - Organoids Market
Report CoverageDetails
Market Size Value inUS$ 2,507.28 million in 2022
Market Size Value byUS$ 8,121.45 million by 2028
Growth rateCAGR of 21.8% from 2023 to 2028
Forecast Period2023-2028
Base Year2022
No. of Pages196
No. of Tables83
No. of Charts & Figures80
Historical data availableYes
Segments coveredType, Application, Source, and Geography
Free Sample Copy Available

Market Insights

Increasing Demand for Tumor Modeling and Biobanking Drives Organoids Market Growth

Organoids are microscopic and self-organizing 3D structures grown from stem cells in vitro. They review various structural and functional characteristics of their in vivo counterpart organs. This multipurpose technology has led to several novel human cancer models. It is now possible to create indefinitely expanding organoids starting from the tumor tissue of individuals suffering from a range of carcinomas. Alternatively, CRISPR-based gene modification allows the engineering of organoid models of cancer by introducing any combination of cancer gene alterations to normal organoids. Tumor organoids, when combined with immune cells and fibroblasts, become a model for the cancer microenvironment enabling immune-oncology applications. Also, recent studies have proved that organoids have a place in personalized medicine approaches.

The constant progress in organoid technology has paved the way for tumors and patient-centric 3D cultures of cells isolated from tumor biopsies. Over the past few decades, organoids have been generated from diverse human cancers associated with breast, colon, pancreas, prostate, bladder, and liver. Studies involving these models help in providing key facts about these malignancies. Due to constant advancements in the current scenario, tumoroid lines are increasingly being passed in vitro, opening new paths for a range of downstream applications. Moreover, 3D-based cultures offer added advantages over conventional 2D cancer-derived cell lines. Further, recent research and development activities have specified that tumoroid culturing is highly effective in allowing the collection of various cancer subtypes from a large pool of patients. As organoids can be easily derived and expanded from single cancer cells, the adoption of organoids to mimic intratumor diversification in culture is increasing, which, in turn, is propelling the global organoids market.

Companies have been developing innovative biobanks for storing several biological samples, including tumors. For instance, OrganoidBase (developed by Crown Bioscience) consists of 342 tumor organoid models derived from patient-derived xenograft (PDX) models [i.e., PDX-derived organoids (PDXOs)]. PDXOs offer detailed information on histopathology, IC50, genomic, and transcriptomic analysis data associated with drug response; it also has an additional 217 models from primary patient samples. These PDXO models have varied indications, with multiple models derived from over 20 organ and tissue types. Crown Biosciences commercializes organoids in a 3D in vitro model derived using IP-protected Hubrecht Organoid Technology (HUB) protocols. Thus, such innovations are driving market growth.

Type-Based Insights

Based on type, the organoids market is segmented into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. In 2022, the intestine segment held the largest share of the market and the stomach segment is anticipated to register the highest CAGR during the forecast period.

Organoids Market, by Product Type – 2022–2028

Organoids Market, by Product Type – 2022–2028

Get more information on this report :

Application-Based Insights

Based on application, the organoids market is divided into developmental biology, disease pathology of infectious disease, regenerative medicine, drug toxicity and efficacy testing, drug discovery and personalized medicine, and others. In 2022, the developmental biology held the largest share of the market and drug discovery & personalized medicine is anticipated to register the highest CAGR during the forecast period.

Source-Based Insights

Based on source, the organoids market is bifurcated into pluripotent stem cells and organ-specific adult stem cells. The pluripotent stem cells segment held a larger share of the market in 2022 and is expected to record at a higher CAGR during the forecast period.

The organoids market players adopt organic strategies, such as product launch and expansion, to expand their footprint and product portfolio across the world and meet the growing demand. Inorganic growth strategies witnessed in the market are partnerships and collaborations. These growth strategies have allowed the market players to expand their businesses and enhance their geographic presence. Additionally, acquisitions, partnerships, and other growth strategies help strengthen the company’s customer base and increase its product portfolio.

  • In May 2020, UK-headquartered iPSC disease modeling company DefiniGEN has identified iPSC-derived intestinal organoids that could be used to help structure in vitro studies of the biology of SARS-CoV2 infection across cohorts of multiple patients.
  • In August 2021, InSphero AG announced that it is making its proprietary, patented 96- and 384-microwell plates available to researchers, enabling them to access the same plate technology used in the company’s flagship, assay-ready 3D InSight Human Liver Microtissues. The plates, engineered specifically for 3D cultures of spheroids and organoids, are available via InSphero’s online R&D Solutions Store.
  • In March 2023, Molecular Devices, LLC. and HUB Organoids (HUB), announced a strategic collaboration enabling continued development of next-generation 3D biology technologies that drive step-change reduction in pre-clinical to clinical drug attrition.

Under the terms of the agreement, Molecular Devices will license cutting-edge HUB Organoid Technology to work with patient-derived intestinal organoids, expanding Molecular Devices’ 3D biology expertise beyond organoid types like the heart and brain.

In February 2023, Thermo Fisher Scientific and Celltrio collaborated to bring a fully automated cell culture system to biotherapeutics customers.

The collaboration will integrate the Thermo Scientific Momentum workflow scheduling software with the Celltrio RoboCell cell line automation platform to address the unmet market need for high-throughput automated cell line culturing and maintenance.

In April 2023, InSphero AG announced that the company is making their patented Akura 96 and 384 Spheroid Microplates available to researchers in the Indian market by signing a distribution agreement with Bionova Supplies in the Biotechnology and Scientific Instruments field in India.

Company Profiles

  • STEMCELL Technologies Inc.
  • Cellesce Ltd
  • Hubrecht Organoid TechnologY
  • Definigen  
  • Organoid Therapeutics
  • PeproTech, Inc
  • Thermo Fisher Scientific Inc  
  • Corning Inc
  • Merck KGaA
  • InSphero

Frequently Asked Questions

The factors that are driving the growth of the market are growth are increasing demand for tumor modeling and biobanking, growing adoption of personalized drugs, and rising focus on developing alternatives for animal testing models propelling market growth.
Organoid is a tiny, self-organized, three-dimensional tissue culture that is derived from stem cells. Such culture is crafted to replicate much of the complexity of an organ or to express selected aspects of it, like producing only certain types of cells. Organoids grow from stem cells—cells that can divide indefinitely and produce different types of cells as part of their progeny. Organoids can range in size from less than the width of a hair to five millimeters..
The organoids market is analyzed on the basis of type, application, and source. Based on type, the segment is divided into stomach, intestine, liver, pancreas, lung, brain, kidney, and others. The intestine segment held the largest market share in 2022, and stomach is anticipated to register the highest CAGR during the forecast period.
The organoids market majorly consists of the players such as STEMCELL Technologies Inc; Cellesce Ltd; Hubrecht Organoid Technology; Definigen; Organoid Therapeutics; PeproTech, Inc; Thermo Fisher Scientific Inc; Corning Inc; Merck KGaA, and InSphero.

The List of Companies - Organoids Market

  1. STEMCELL Technologies Inc
  2. Cellesce Ltd
  3. Hubrecht Organoid Technology
  4. Definigen
  5. Organoid Therapeutics
  6. PeproTech, Inc
  7. Thermo Fisher Scientific Inc
  8. Corning Inc
  9. Merck KGaA
  10. InSphero.
  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the organoids market.
  • Highlights key business priorities in order to assist companies to realign their business strategies.
  • The key findings and recommendations highlight crucial progressive industry trends in the global organoids market, thereby allowing players across the value chain to develop effective long-term strategies.
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets.
  • Scrutinize in-depth global market trends and outlook coupled with the factors driving the organoids market, as well as those hindering it.
  • Enhance the decision-making process by understanding the strategies that underpin security interest with respect to client products, segmentation, pricing, and distribution.
Your data will never be shared with third parties, however, we may send you information from time to time about our products that may be of interest to you. By submitting your details, you agree to be contacted by us. You may contact us at any time to opt-out.

Get the Latest COVID-19 Analysis on this market

Have a Question?

Akshay will walk you through a 15-minute call to present the report’s content and answer all queries if you have any.

Speak to Analyst
  • $3000
  • $4550
  • $6550
  • $8550

Sample PDF showcases the content structure and the nature of the information included in the report which presents a qualitative and quantitative analysis.

    Inquire for Discount